Home › Articles

Access & affordability

Compounded tirzepatide vs. Mounjaro: why patients are asking, and how it fits a practice

PeptideClinicians editorial team · [MEDICAL/CLINICAL REVIEWER – JOHN TO CONFIRM]

Tirzepatide, the active ingredient in Eli Lilly's Mounjaro, has become one of the most requested medications in metabolic and weight-management care. For many patients, the barrier isn't interest. It's access: out-of-pocket cost for the brand-name product, inconsistent insurance coverage, prior authorization requirements and, at times, supply constraints.

As a result, patients increasingly arrive asking about compounded tirzepatide, prepared by a licensed compounding pharmacy pursuant to an individual prescription.

Why patients seek it out

What to keep in mind clinically

How it fits a practice

For many practices, a tirzepatide program is the entry point to a broader peptide and metabolic-health service line: an initial evaluation, a cash-pay medication plan, and scheduled follow-ups (in person or via telehealth). Program economics: [PROGRAM PRICING / MARGIN EXAMPLE – JOHN TO CONFIRM]. Cascadia's practice consultants can walk you through pharmacy partners, workflows and patient education materials.

Next live webinar: "How to Incorporate Peptides into your Practice" · Tuesday, November 10, 2026 · 1:00 PM PT / 4:00 PM ET
RSVP for the next webinar Talk to a practice consultant
Get a free state- and peptide-specific compliance memo + informed consent template →

More articles

Get our educational materials

Clinician-focused articles, protocols overviews and webinar invitations. No spam; opt out any time.

Send me educational materials by:

Optional, and not required to submit. [FORM DISCLOSURE / TERMS & PRIVACY ACKNOWLEDGMENT – JOHN TO PROVIDE] See Terms and Privacy.